| Q36907857 | A CALM-derived nuclear export signal is essential for CALM-AF10-mediated leukemogenesis |
| Q28577939 | A Nuclear Attack on Traumatic Brain Injury: Sequestration of Cell Death in the Nucleus |
| Q44714283 | A chemical genetic screen identifies inhibitors of regulated nuclear export of a Forkhead transcription factor in PTEN-deficient tumor cells |
| Q38975042 | A critical role for CRM1 in regulating HOXA gene transcription in CALM-AF10 leukemias. |
| Q38812797 | A method for quantification of exportin-1 (XPO1) occupancy by Selective Inhibitor of Nuclear Export (SINE) compounds |
| Q40144345 | Abrogation of ionizing radiation-induced G2 checkpoint and inhibition of nuclear export by Cryptocarya pyrones. |
| Q56996774 | Advancements in Host-Based Interventions for Influenza Treatment |
| Q37514846 | Altered nucleophosmin transport in acute myeloid leukaemia with mutated NPM1: molecular basis and clinical implications. |
| Q36023740 | An evaluation of small-molecule p53 activators as chemoprotectants ameliorating adverse effects of anticancer drugs in normal cells |
| Q38738390 | Anti-tumor activity of selective inhibitor of nuclear export (SINE) compounds, is enhanced in non-Hodgkin lymphoma through combination with mTOR inhibitor and dexamethasone |
| Q38878268 | Anti-tumor activity of selective inhibitors of XPO1/CRM1-mediated nuclear export in diffuse malignant peritoneal mesothelioma: the role of survivin. |
| Q58774746 | Anti-tumor efficacy of Selinexor (KPT-330) in gastric cancer is dependent on nuclear accumulation of p53 tumor suppressor |
| Q27670981 | Antileukemic activity of nuclear export inhibitors that spare normal hematopoietic cells |
| Q35111192 | Antitumor effects of a novel chromosome region maintenance 1 (CRM1) inhibitor on non-small cell lung cancer cells in vitro and in mouse tumor xenografts |
| Q33940712 | Atomic basis of CRM1-cargo recognition, release and inhibition |
| Q35014385 | Awakening guardian angels: drugging the p53 pathway |
| Q35206543 | Biologic activity of the novel orally bioavailable selective inhibitor of nuclear export (SINE) KPT-335 against canine melanoma cell lines |
| Q35828737 | Biology of chronic myeloid leukemia and possible therapeutic approaches to imatinib-resistant disease |
| Q38708600 | Breakthrough therapies in B-cell non-Hodgkin lymphoma. |
| Q36483749 | Broad targeting of resistance to apoptosis in cancer. |
| Q39431526 | CRM1 Inhibitors for Antiviral Therapy |
| Q37445828 | CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications. |
| Q37330941 | CRM1/XPO1 is associated with clinical outcome in glioma and represents a therapeutic target by perturbing multiple core pathways |
| Q26772873 | Capturing Biological Activity in Natural Product Fragments by Chemical Synthesis |
| Q39674045 | Changing the subcellular location of the oncoprotein Bcr-Abl using rationally designed capture motifs |
| Q34929081 | Combination therapy with imatinib mesylate (STI571): synopsis of in vitro studies |
| Q36592228 | Controlling protein compartmentalization to overcome disease |
| Q59813350 | Controlling the Gatekeeper: Therapeutic Targeting of Nuclear Transport |
| Q64967545 | Crm1 knockdown by specific small interfering RNA reduces cell proliferation and induces apoptosis in head and neck cancer cell lines. |
| Q35843010 | Deciphering mechanisms of drug sensitivity and resistance to Selective Inhibitor of Nuclear Export (SINE) compounds |
| Q57099831 | Decrease of 5-hydroxymethylcytosine and TET1 with nuclear exclusion of TET2 in small intestinal neuroendocrine tumors |
| Q59812349 | Does Size Really Matter? Probing the Efficacy of Structural Reduction in the Optimization of Bioderived Compounds - A Computational "Proof-of-Concept" |
| Q40911261 | Effects on normal fibroblasts and neuroblastoma cells of the activation of the p53 response by the nuclear export inhibitor leptomycin B. |
| Q35422300 | Epigallocatechin-3-gallate enhances the therapeutic effects of leptomycin B on human lung cancer a549 cells |
| Q36640945 | Evaluation of rodent-only toxicology for early clinical trials with novel cancer therapeutics |
| Q35920569 | Expression, function, and targeting of the nuclear exporter chromosome region maintenance 1 (CRM1) protein |
| Q33430367 | First-in-Class, First-in-Human Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Patients With Advanced Solid Tumors |
| Q39141673 | Genome-wide studies in multiple myeloma identify XPO1/CRM1 as a critical target validated using the selective nuclear export inhibitor KPT-276. |
| Q39094551 | High-content screening of natural products reveals novel nuclear export inhibitors |
| Q90383564 | Host-HIV-1 Interactome: A Quest for Novel Therapeutic Intervention |
| Q37347745 | Human multiple myeloma cells are sensitized to topoisomerase II inhibitors by CRM1 inhibition |
| Q37081966 | Identification of nuclear export inhibitors with potent anticancer activity in vivo |
| Q28547505 | Identification of the Lipodepsipeptide MDN-0066, a Novel Inhibitor of VHL/HIF Pathway Produced by a New Pseudomonas Species |
| Q35123468 | Improving cancer therapy by non-genotoxic activation of p53. |
| Q31929753 | Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR-ABL tyrosine kinase. |
| Q89700428 | Inhibiting cancer cell hallmark features through nuclear export inhibition |
| Q34410193 | Inhibition of CRM1-dependent nuclear export sensitizes malignant cells to cytotoxic and targeted agents |
| Q33918079 | KPT-330 has antitumour activity against non-small cell lung cancer |
| Q52715766 | KPT-330 inhibition of chromosome region maintenance 1 is cytotoxic and sensitizes chronic myeloid leukemia to Imatinib. |
| Q34098446 | KPT-330 inhibitor of XPO1-mediated nuclear export has anti-proliferative activity in hepatocellular carcinoma |
| Q35856215 | KPT-330, a potent and selective exportin-1 (XPO-1) inhibitor, shows antitumor effects modulating the expression of cyclin D1 and survivin [corrected] in prostate cancer models. |
| Q47754114 | Leptomycin B reduces primary and acquired resistance of gefitinib in lung cancer cells |
| Q26764837 | Mechanisms of Nuclear Export in Cancer and Resistance to Chemotherapy |
| Q27343176 | MicroRNA-1301-Mediated RanGAP1 Downregulation Induces BCR-ABL Nuclear Entrapment to Enhance Imatinib Efficacy in Chronic Myeloid Leukemia Cells |
| Q37702556 | Molecular mechanism and therapeutic implications of selinexor (KPT-330) in liposarcoma |
| Q27712238 | Next-generation XPO1 inhibitor shows improved efficacy and in vivo tolerability in hematological malignancies |
| Q35732942 | Novel reversible selective inhibitor of CRM1 for targeted therapy in ovarian cancer |
| Q36214313 | Novel reversible selective inhibitor of nuclear export shows that CRM1 is a target in colorectal cancer cells |
| Q33945804 | Novel small molecule XPO1/CRM1 inhibitors induce nuclear accumulation of TP53, phosphorylated MAPK and apoptosis in human melanoma cells |
| Q55040338 | Nuclear Export Inhibition for Pancreatic Cancer Therapy. |
| Q27675810 | Nuclear export inhibition through covalent conjugation and hydrolysis of Leptomycin B by CRM1 |
| Q38310025 | Nuclear export inhibitor leptomycin B induces the appearance of novel forms of human Mdm2 protein. |
| Q34204130 | Nuclear export mediated regulation of microRNAs: potential target for drug intervention |
| Q27012444 | Nuclear export of proteins and drug resistance in cancer |
| Q33976883 | Nuclear retention of Fbw7 by specific inhibitors of nuclear export leads to Notch1 degradation in pancreatic cancer |
| Q35633427 | Nuclear transport and cancer: from mechanism to intervention |
| Q35058962 | Nuclear transport as a target for cell growth |
| Q34452108 | Nucleo-cytoplasmic transport as a therapeutic target of cancer |
| Q43619746 | Optimized transformation of Streptomyces sp. ATCC 39366 producing leptomycin by electroporation |
| Q83835605 | Overexpression of Jun activation domain-binding protein 1 in nonsmall cell lung cancer and its significance in p27 expression and clinical features |
| Q36489494 | Pharmacodynamic and genomic markers associated with response to the XPO1/CRM1 inhibitor selinexor (KPT-330): A report from the pediatric preclinical testing program. |
| Q42911898 | Potential effects of CRM1 inhibition in mantle cell lymphoma |
| Q36206410 | Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemia |
| Q37263168 | Preclinical and clinical efficacy of XPO1/CRM1 inhibition by the karyopherin inhibitor KPT-330 in Ph+ leukemias |
| Q35087639 | Preclinical evaluation of the novel, orally bioavailable Selective Inhibitor of Nuclear Export (SINE) KPT-335 in spontaneous canine cancer: results of a phase I study |
| Q60138277 | Protection from Disulfide Stress by Inhibition of Pap1 Nuclear Export in |
| Q34449212 | Protein-reactive natural products |
| Q35128883 | Resistance of Philadelphia-chromosome positive leukemia towards the kinase inhibitor imatinib (STI571, Glivec): a targeted oncoprotein strikes back |
| Q26796151 | Respiratory virus modulation of host nucleocytoplasmic transport; target for therapeutic intervention? |
| Q36710840 | Restoration of wild-type p53 function in human cancer: relevance for tumor therapy. |
| Q39205536 | Reviving the guardian of the genome: Small molecule activators of p53. |
| Q34441666 | SINE (selective inhibitor of nuclear export)--translational science in a new class of anti-cancer agents |
| Q36078792 | Selective Nuclear Export Inhibitor KPT-330 Enhances the Antitumor Activity of Gemcitabine in Human Pancreatic Cancer |
| Q57351344 | Selective induction of apoptosis by leptomycin B in keratinocytes expressing HPV oncogenes |
| Q38975190 | Selective inhibitors of nuclear export (SINE) as novel therapeutics for prostate cancer |
| Q38368605 | Selective inhibitors of nuclear export (SINE) in hematological malignancies |
| Q38260357 | Selective inhibitors of nuclear export (SINE)--a novel class of anti-cancer agents |
| Q36675242 | Selective inhibitors of nuclear export block pancreatic cancer cell proliferation and reduce tumor growth in mice |
| Q41470933 | Selective inhibitors of nuclear export for the treatment of non-Hodgkin's lymphomas |
| Q27674083 | Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia |
| Q41550563 | Selinexor (KPT-330) has antitumor activity against anaplastic thyroid carcinoma in vitro and in vivo and enhances sensitivity to doxorubicin. |
| Q96647251 | Small Molecule Inhibitors of CRM1 |
| Q34817365 | Small molecule inhibitors in acute myeloid leukemia: from the bench to the clinic |
| Q38222341 | Snail nuclear transport: the gateways regulating epithelial-to-mesenchymal transition? |
| Q26781513 | Structural Basis of Targeting the Exportin CRM1 in Cancer |
| Q99551845 | Targeted CRM1-inhibition perturbs leukemogenic NUP214 fusion proteins and exerts anti-cancer effects in leukemia cell lines with NUP214 rearrangements |
| Q97093743 | Targeting nuclear import and export in hematological malignancies |
| Q34398166 | Targeting nucleocytoplasmic transport in cancer therapy |
| Q44204547 | Targeting survivin's co-conspirators: do alternative methods of trapping survivin in the nucleus have potential in triple-negative breast cancer therapy? |
| Q27307611 | Targeting the Nuclear Export Protein XPO1/CRM1 Reverses Epithelial to Mesenchymal Transition |
| Q40586178 | The CRM1 nuclear export receptor controls pathological cardiac gene expression |
| Q64881075 | The nuclear export inhibitor aminoratjadone is a potent effector in extracellular-targeted drug conjugates. |
| Q101564368 | The nuclear export protein XPO1 - from biology to targeted therapy |
| Q64107227 | The past, present, and future of CRM1/XPO1 inhibitors |
| Q48743003 | Therapeutic Targeting of Nuclear Export Inhibition in Lung Cancer |
| Q101564352 | Therapeutic strategies targeting FOXO transcription factors |
| Q47549703 | Verdinexor Targeting of CRM1 is a Promising Therapeutic Approach against RSV and Influenza Viruses |
| Q30363986 | Verdinexor, a novel selective inhibitor of nuclear export, reduces influenza a virus replication in vitro and in vivo. |
| Q66679726 | Viral Appropriation: Laying Claim to Host Nuclear Transport Machinery |
| Q64944710 | XPO1 Expression Is a Poor-Prognosis Marker in Pancreatic Adenocarcinoma. |
| Q47113773 | XPO1 target occupancy measurements confirm the selinexor recommended phase 2 dose |
| Q35602930 | XPO1/CRM1 Inhibition Causes Antitumor Effects by Mitochondrial Accumulation of eIF5A. |
| Q37750115 | p53-based cancer therapy |